Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combined With Intraperitoneal Paclitaxel in High-Grade Metastatic Appendiceal Adenocarcinoma
NCT07753824Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2027
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in appendiceal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and Disease Control Rate up to 2 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
appendiceal adenocarcinoma
Beyond the preview
Go deeper on NCT07753824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753824.